Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06079190




Registration number
NCT06079190
Ethics application status
Date submitted
6/10/2023
Date registered
12/10/2023
Date last updated
14/02/2024

Titles & IDs
Public title
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Scientific title
A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
Secondary ID [1] 0 0
2023-505083-11-00
Secondary ID [2] 0 0
219867
Universal Trial Number (UTN)
Trial acronym
PROGRESS-AD
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GSK4527226
Other interventions - Placebo

Experimental: GSK4527226 Dose 1 - Participants will receive GSK4527226 Dose 1

Experimental: GSK4527226 Dose 2 - Participants will receive GSK4527226 Dose 2

Placebo Comparator: Placebo - Participants will receive placebo.


Treatment: Drugs: GSK4527226
GSK4527226 will be administered.

Other interventions: Placebo
Placebo will be administered.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [1] 0 0
Baseline, Week 52, 64 and 76
Secondary outcome [1] 0 0
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [1] 0 0
Baseline, Weeks 52, 64 and 76
Secondary outcome [2] 0 0
Change from Baseline in ADAS-Cog14 Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [2] 0 0
Baseline, Weeks 52, 64 and 76
Secondary outcome [3] 0 0
Change from Baseline in ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [3] 0 0
Baseline, Weeks 52, 64 and 76
Secondary outcome [4] 0 0
Change from Baseline in ADCS-iADL component of ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [4] 0 0
Baseline, Weeks 52, 64 and 76
Secondary outcome [5] 0 0
Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) for Dose 1 vs Placebo Across Weeks 52, 64 and 76
Timepoint [5] 0 0
Baseline, Weeks 52, 64 and 76

Eligibility
Key inclusion criteria
Participant must be in the Alzheimer's continuum as defined by the 2018 National Institute
on Aging and Alzheimer's Association (NIAAA) Research Framework corresponding to the
clinical categories of MCI due to AD and mild AD dementia.

Participant must have evidence of amyloid positivity either by positive positron emission
tomography (PET) result (Amyloid PET scans must be read by a central imaging lab) or
cerebrospinal fluid (CSF) amyloid beta (Aß) test result indicative of amyloid positivity

- Participants must also meet the following criteria for clinical severity:

1. MMSE score of between 21 and 29 points

2. CDR-global score (GS) of 0.5 to 1.0.

3. CDR Memory Box score greater than or equal to (=) 0.5.

4. Participants with objective impairment in episodic memory as indicated by at
least 1 standard deviation below age-adjusted mean in the Wechsler Memory
Scale-IV Logical Memory II (WMS-IV LMII)

- If the participant is receiving symptomatic AD medications such as an
Acetylcholinesterase inhibitor (AChEI) or memantine, the dosing regimen must have been
stable for at least 12 weeks prior to screening and is not expected to change during
study participation.

- If the participant is receiving other medications for AD related symptoms or
associated conditions, the dosing regimen must have been stable for at least 4 weeks
prior to screening and not expected to change during study participation. Symptoms
must be considered adequately and stably controlled by the investigator, without
marked changes in medication anticipated for the duration of the study.

- Body weight = 45 kilogram (kg) to less than or equal to (=)120 kg with body mass index
(BMI) between 17 and 34.9 kilogram per meter square (kg/m^2), inclusive.

- A female participant is eligible to participate if she is not pregnant or
breastfeeding, and if of child-bearing potential follows contraception requirements
outlined in the protocol

- A male participant is eligible to participate if he follows contraception requirements
outlined in the protocol

- Willing and able to give informed consent which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF).

- Availability of an adult person who has frequent and sufficient contact with the
participant is able to provide accurate information regarding the participant's
cognitive and functional abilities, agrees to provide information at clinic visits,
and signs the ICF of the study partner.
Minimum age
50 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Participant has evidence of any neurological condition other than AD that may contribute to
cognitive impairment.

- History or presence of vascular disease that has the potential to affect cognitive
function.

- History or presence of stroke within the past 1 year or recent transient ischemic
attack within 180 days before screening.

- History of severe, clinically significant central nervous system (CNS) trauma.

- History or presence of intracranial tumor.

- Presence of ongoing infection(s) that may affect brain function, or history of
infections that resulted in neurologic sequelae.

- History of primary psychiatric diagnosis that the investigator considers may interfere
with study assessments.

Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, suicidal
behaviour or has been assessed to be at risk of suicide, in the opinion of the investigator
within 6 months before screening, at screening, or at the Baseline visit, or has been
hospitalized or treated for suicidal behaviour in the past 2 years.

- Participant has history of alcohol and/or moderate to severe substance use disorder
within the past 2 years

- Magnetic resonance imaging (MRI) evidence based on central read of:

1. >3 lacunar infarcts.

2. Stroke involving a major vascular territory, severe small vessel, or white matter
disease.

3. Any territorial infarct >1 cubic centimetre (cm^3).

4. White matter hyperintense lesions on the FLAIR sequence that correspond to an
overall Fazekas score of 3

5. >4 microhaemorrhages.

6. Any areas of superficial (leptomeningeal) hemosiderosis.

7. A single macro-hemorrhage greater than 10 millimetres (mm) at greatest diameter.

8. Vasogenic edema.

9. Cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or
infective lesions.

10. Space occupying lesions or brain tumors.

11. Significant cerebral vascular pathology

- History suggestive of exposure to, or past tuberculosis (TB) infection should undergo
screening for TB disease.

- Chronic active immune disorder requiring systemic immunosuppressive therapy within 6
months prior to Screening.

- Screening serum vitamin B12 concentration < Lower limit of normal (LLN) or in the low
normal range

- Folate <LLN or Thyroid-stimulating hormone (TSH) > Upper limit of normal (ULN)

- Hemoglobin A1c >8 percentage (%) or poorly controlled diabetes during the last 12
weeks

- History of cancer

- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric, human, or humanized antibodies or fusion proteins

- Planned surgery during the study which requires general, spinal, or epidural
anesthesia that would take place during the study.

- Key exclusionary medications include:

- Antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood
stabilizers, or stimulants that are used on a chronic basis, are exclusionary if
not consistent with the following rule: treatment has to have been at a stable
dose for at least 4 weeks before screening and should remain stable during the
study

- Any biologic drugs with systemic exposure, whether investigational or approved,
used within 6 months before screening Any disease modification drug for AD, such
as aducanumab and lecanemab, whether investigational or approved, used within 6
months before screening.

- Anticoagulation medications within 90 days of screening and during the study

- Systemic immunosuppressive therapy within 90 days before screening and during the
study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/10/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/05/2029
Actual
Sample size
Target
282
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Camperdown
Recruitment hospital [2] 0 0
GSK Investigational Site - Darlinghurst
Recruitment hospital [3] 0 0
GSK Investigational Site - Kogarah
Recruitment hospital [4] 0 0
GSK Investigational Site - Macquarie Park
Recruitment hospital [5] 0 0
GSK Investigational Site - Southport
Recruitment hospital [6] 0 0
GSK Investigational Site - Ivanhoe
Recruitment hospital [7] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [8] 0 0
GSK Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
2217 - Kogarah
Recruitment postcode(s) [4] 0 0
2113 - Macquarie Park
Recruitment postcode(s) [5] 0 0
4222 - Southport
Recruitment postcode(s) [6] 0 0
3079 - Ivanhoe
Recruitment postcode(s) [7] 0 0
3004 - Melbourne
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New Jersey
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Oklahoma
Country [12] 0 0
United States of America
State/province [12] 0 0
Oregon
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
Canada
State/province [18] 0 0
Quebec
Country [19] 0 0
Finland
State/province [19] 0 0
Helsinki
Country [20] 0 0
Finland
State/province [20] 0 0
Kuopio
Country [21] 0 0
Finland
State/province [21] 0 0
Oulu
Country [22] 0 0
Finland
State/province [22] 0 0
Turku
Country [23] 0 0
France
State/province [23] 0 0
Bron
Country [24] 0 0
France
State/province [24] 0 0
Lille Cedex
Country [25] 0 0
France
State/province [25] 0 0
Nice
Country [26] 0 0
France
State/province [26] 0 0
Paris
Country [27] 0 0
France
State/province [27] 0 0
Saint-Herblain
Country [28] 0 0
France
State/province [28] 0 0
Strasbourg
Country [29] 0 0
France
State/province [29] 0 0
Toulouse
Country [30] 0 0
France
State/province [30] 0 0
Villeurbanne
Country [31] 0 0
Germany
State/province [31] 0 0
Bayern
Country [32] 0 0
Germany
State/province [32] 0 0
Hessen
Country [33] 0 0
Germany
State/province [33] 0 0
Nordrhein-Westfalen
Country [34] 0 0
Italy
State/province [34] 0 0
Lazio
Country [35] 0 0
Italy
State/province [35] 0 0
Liguria
Country [36] 0 0
Italy
State/province [36] 0 0
Modena
Country [37] 0 0
Italy
State/province [37] 0 0
Palermo
Country [38] 0 0
Italy
State/province [38] 0 0
Pavia
Country [39] 0 0
Italy
State/province [39] 0 0
Brescia
Country [40] 0 0
Italy
State/province [40] 0 0
Milano
Country [41] 0 0
Italy
State/province [41] 0 0
Monza
Country [42] 0 0
Italy
State/province [42] 0 0
Perugia
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Jung Gu
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Seoul
Country [45] 0 0
Netherlands
State/province [45] 0 0
's-Hertogenbosch
Country [46] 0 0
Netherlands
State/province [46] 0 0
Amsterdam
Country [47] 0 0
Netherlands
State/province [47] 0 0
Zwolle
Country [48] 0 0
Norway
State/province [48] 0 0
Bergen
Country [49] 0 0
Norway
State/province [49] 0 0
Drammen
Country [50] 0 0
Norway
State/province [50] 0 0
Oslo
Country [51] 0 0
Norway
State/province [51] 0 0
Stavanger
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Spain
State/province [53] 0 0
País Vasco
Country [54] 0 0
Spain
State/province [54] 0 0
Barcelona
Country [55] 0 0
Spain
State/province [55] 0 0
Getxo
Country [56] 0 0
Spain
State/province [56] 0 0
Pamplona
Country [57] 0 0
Spain
State/province [57] 0 0
Salamanca
Country [58] 0 0
Spain
State/province [58] 0 0
Terrassa (Barcelona)
Country [59] 0 0
Spain
State/province [59] 0 0
Valencia
Country [60] 0 0
Sweden
State/province [60] 0 0
Jönköping
Country [61] 0 0
Sweden
State/province [61] 0 0
Malmö
Country [62] 0 0
Sweden
State/province [62] 0 0
Mölndal
Country [63] 0 0
Sweden
State/province [63] 0 0
Stockholm
Country [64] 0 0
Taiwan
State/province [64] 0 0
Kaohsiung
Country [65] 0 0
Taiwan
State/province [65] 0 0
Tainan
Country [66] 0 0
Taiwan
State/province [66] 0 0
Taoyuan
Country [67] 0 0
Turkey
State/province [67] 0 0
Ankara
Country [68] 0 0
Turkey
State/province [68] 0 0
Capa/Istanbul
Country [69] 0 0
United Kingdom
State/province [69] 0 0
England
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Bristol
Country [71] 0 0
United Kingdom
State/province [71] 0 0
London
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Motherwell

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Alector Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with
early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia
due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06079190
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
US GSK Clinical Trials Call Center
Address 0 0
Country 0 0
Phone 0 0
877-379-3718
Fax 0 0
Email 0 0
GSKClinicalSupportHD@gsk.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06079190